Silence Therapeutics is snatching back two siRNA drug targets developed through a $20 million collaboration with Mallinckrodt. The two companies agreed in 2019 to develop three siRNA drug targets that would silence the complement cascade in complement-mediated disorders. But now Silence wants the other two programs back to continue work, according to a Tuesday press release. Source: Fierce Biotech 28/3/2023